Group 1 - The company held the 15th meeting of the 10th Supervisory Board on June 13, 2025, with all three supervisors participating in the voting, which complied with relevant regulations [2][4] - The Supervisory Board approved the financial write-off of asset losses, with a total original value of inventory and fixed assets amounting to 1,789,961.56 yuan and an estimated loss of 978,888.18 yuan, impacting the total profit for 2024 by 825,135.58 yuan [3][4] - The financial write-off will not affect the company's profit and loss for the year 2025, as the impact has already been accounted for in previous years [3] Group 2 - The company announced the proposed cancellation of its subsidiary, Guangxi Wuzhou Zhongheng Pharmaceutical (Hong Kong) Co., Ltd., during the 29th meeting of the 10th Board of Directors held on June 13, 2025 [7][12] - The reason for the cancellation is that the subsidiary has not engaged in substantial operations since its establishment, and the company aims to optimize its organizational structure and improve operational efficiency [8] - The cancellation will not involve personnel arrangements and is not expected to have a significant impact on the company's financial and operational status [9] Group 3 - The Board of Directors approved the establishment of the "Overseas Investment Management Measures" and the "Financing Guarantee Management Measures," as well as the revision of the "Financing Management System" [13][15][16] - All resolutions passed with unanimous support from the board members, indicating strong consensus on these governance measures [14][15]

本次注销事项不构成关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。根据《上海证券交易所股票上市规则》《公司章程》等相 关规定，公司本次注销事项在董事会审批权限范围内，无需提交股东大会审议。 具体情况如下： | 名称 | 中恒集团梧州制药（香港）有限公司 | | --- | --- | | 负责人 | 彭伟民 | | 注册资本 | 港元 30,625,500 | | 成立日期 | 年 月 2015 2 | | 成立地址 | 中国香港 | | 住所 | 目前在香港无实际营业场所及办公场所 | | 企业境外投资证书核准或备案文号 | 桂境外投资[2015]N00004 号 | | 经营范围（业务性质） | 主营医药产品进出口贸易以及对外投资 | | 股权结构 | 梧州制药认缴出资 港元，持股 30,625,500 100%。截至 | | | 目前，梧州制药实缴出资 0 元。 | | 其他说明 | 梧州制药（香港）公司名下无负债、无资产，未开设银 | | | 行账户。 | 一、拟注销主体基本情况 1 二、注销梧州制药（香港）公司的原因 证券代码：600252 证券简称：中恒集团 公告编号：临 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-58 广西梧州中恒集团股份有限公司 第十届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、监事会会议审议情况 会议审议并以记名投票方式表决通过：《广西梧州中恒集团股份有限公司关 于资产损失财务核销的议案》。 本次拟核销的存货以及固定资产原值 1,789,961.56 元，预计损失 978,888.18 元，其中影响 2024 年度利润总额为 825,135.58 元，本次财务核销事项所产生的 影响已计入 2024 年度及以前年度的损益，根据会计准则，该事项不会对公司 2025 年度损益产生影响。 表决结果：同意 3 票，反对 0 票，弃权 0 票，回避 0 票。 三、备查文件 中恒集团第十届监事会第十五次会议决议。 特此公告。 一、监事会会议召开情况 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）第十 届监事会第十五次会议通知和议案材料于 2025 年 6 月 11 日以电子邮件的方式发 出，会议于 2025 年 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-57 广西梧州中恒集团股份有限公司 第十届董事会第二十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）第十 届董事会第二十九次会议通知和议案材料于 2025 年 6 月 11 日以电子邮件的方式 发出，会议于 2025 年 6 月 13 日以现场结合通讯方式在广西南宁市江南区高岭路 100 号办公楼会议室召开，公司董事长杨金海先生以通讯方式出席并主持会议。 会议应参加表决董事 7 人，实际参加表决董事 7 人，董事王海润先生、徐诗玥 女士、陈虎先生出席现场会议，其他董事以通讯方式参加。会议的召集和召开 符合《公司法》《公司章程》和《公司董事会议事规则》的有关规定。 二、董事会会议审议情况 （一）会议审议通过《广西梧州中恒集团股份有限公司关于制定<广西梧州 中恒集团股份有限公司境外投资管理办法>的议案》 董事会同意制定《广西梧州中恒集团股份有限公司境外投资管理 ...

Core Viewpoint - Central Huijin has heavily invested in five low-priced stocks, indicating a potential new wave of market growth, with expectations of significant returns similar to past investments [1][3]. Group 1: Central Huijin's Investment Strategy - Central Huijin has a history of successful investments, such as in Luzhou Laojiao in 2015, Northern Huachuang in 2018, and Changchun Gaoxin in 2019, each achieving tenfold increases [3]. - The current focus is on five low-priced stocks that are expected to experience substantial growth, potentially creating the next tenfold bull stock [3]. Group 2: Specific Stocks Identified - The first stock is Shanghai Construction, a leader in the construction industry, with Central Huijin holding 52.8 million shares [4]. - The second stock is Wenfeng Shares, a leading retail company in Shanghai, with Central Huijin holding 21.95 million shares [5]. - The third stock is Shoukai Shares, which has first-class real estate development qualifications, with Central Huijin holding 38.41 million shares [6]. - The fourth stock is Zhongheng Group, a top profit-generating company in the traditional Chinese medicine industry, with Central Huijin holding 49.78 million shares [7]. - The fifth stock is a global leader in nuclear power engineering, with orders amounting to 44 billion yuan, and has seen significant increases in holdings from both Central Huijin and foreign investors [7].

Core Insights - Zhongheng Group has released its 15th Social Responsibility Report, highlighting its practices in rural revitalization, green low-carbon transformation, and ensuring public welfare, receiving multiple honors including recognition in the ESG Pioneer 100 Index and as an excellent practice case for sustainable development in 2024 [1] Group 1: Green Development and Low-Carbon Transformation - The company is committed to green development, aligning with the national "dual carbon" goals, and has invested in energy conservation, emission reduction, clean production, and renewable energy utilization [1] - Zhongheng promotes green pest control and wild-simulated planting techniques, and is establishing a rescue base for the national second-level protected plant, promoting a green ecological circle for traditional Chinese medicine [1] - The company extends its environmental protection philosophy through activities like World Environment Day and tree planting [1] Group 2: Social Responsibility and Health Care - Zhongheng actively responds to national policies, with multiple products renewing contracts or winning bids in national and provincial centralized procurement, enhancing the accessibility of clinical medications and reducing patient burdens [1] - The company explores a "industry + technology + public welfare" model for rural revitalization, supporting the construction of traditional Chinese medicine material bases to increase farmers' income [1] - Zhongheng integrates intangible cultural heritage techniques with modern production technology to develop new products like sugar-free Liubao tea and black bean milk [1] - The company engages in volunteer services such as the Zhongheng Scholarship, Mother's Smile Initiative, and the Elderly and Children Care Project, continuously delivering warmth to society [1] Group 3: Corporate Governance and Development - Zhongheng focuses on modernizing its governance system, continuously improving its governance structure and establishing a long-term shareholder return mechanism [2] - Since its listing, the company has distributed a total of 2.941 billion yuan in dividends and repurchased nearly 173 million shares, demonstrating confidence in its corporate value [2] - In 2024, Zhongheng plans to establish three new provincial-level research platforms and has been approved for two Guangxi Natural Science Fund projects [2] - The company is advancing the development of innovative traditional Chinese medicine products and has received approvals for multiple drug varieties, solidifying its position in the industry [2] - Zhongheng aims to maintain a pragmatic approach, collaborating with partners to contribute to comprehensive reform and the modernization of China [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600252 证券简称：中恒集团 公告编号：临2025-56 广西梧州中恒集团股份有限公司 关于2025年以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）于2025年1月24日和2025年2月26日分 别召开第十届董事会第二十五次会议和2025年第一次临时股东大会，会议审议通过了《中恒集团关于 2025年以集中竞价交易方式回购股份方案的议案》，同意公司使用自有资金或自筹资金，以不超过3.80 元/股回购公司发行的人民币普通股（A股）股票，用于注销并减少公司注册资本。回购资金总额为不低 于人民币30,000.00万元（含）且不超过人民币50,000.00万元（含）。回购期限为自2025年2月26日召开 的股东大会审议通过回购方案之日起不超过6个月。具体内容详见公司于2025年4月2日在上海证券交易 所网站披露的《中恒集团关于2025年以集中竞价交易方式回购公司股份的回 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-56 广西梧州中恒集团股份有限公司 关于 2025 年以集中竞价交易方式回购公司股份 的进展公告 一、回购股份的基本情况 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）于 2025 年 1 月 24 日和 2025 年 2 月 26 日分别召开第十届董事会第二十五次会议和 2025 年第一次临时股东大会，会议审议通过了《中恒集团关于 2025 年以集中竞价交易 方式回购股份方案的议案》，同意公司使用自有资金或自筹资金，以不超过 3.80 元 /股回购公司发行的人民币普通股（A 股）股票，用于注销并减少公司注册资本。 回购资金总额为不低于人民币 30,000.00 万元（含）且不超过人民币 50,000.00 万 元（含）。回购期限为自 2025 年 2 月 26 日召开的股东大会审议通过回购方案之日 起不超过 6 个月。具体内容详见公司于 2025 年 4 月 2 日在上海证券交易所网站披 露的《中恒集团关于 2025 年以集中竞价交易方式回购公司股份的回购报告书》（公 告编号：临 2025-35）。 1 二、回购股份的进展情 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-55 广西梧州中恒集团股份有限公司 关于控股股东筹划公司控股权内部调整的提示性公告 ●广西梧州中恒集团股份有限公司（以下简称"公司"）控股股东广西投资 集团有限公司（以下简称"广投集团"）拟以其所持有的公司 859,343,587 股（占 公司总股本的 25.94%）无限售条件流通股股份对其控股公司广西投资集团金融 控股有限公司（以下简称"广投金控"）进行增资扩股（以下简称"本次交易"）。 ●目前，广投集团为广投金控的间接控股股东，广投集团、广投金控和公司 的实际控制人均为广西壮族自治区国有资产监督管理委员会（以下简称"广西国 资委"），本次交易属于同一控制下的国有股权变动。本次交易完成后，公司控 股股东将变更为广投金控，公司实际控制人仍为广西国资委。 ●上述事项尚处于筹划阶段，尚需履行国资审批程序及相关法定程序。截至 本公告披露日，广投集团与广投金控尚未签订相关协议。敬请广大投资者理性投 资并注意投资风险。 一、本次交易的基本情况 公司于 2025 年 5 月 30 日收到控股股东广投集团的通知，广投集团拟以其所 持有的公司 859,343 ...

Group 1 - The company, Chongqing Laimei Pharmaceutical Co., Ltd., announces that its indirect controlling shareholder, Guangxi Investment Group Co., Ltd., plans to increase capital in Guangxi Investment Group Financial Holding Co., Ltd. by transferring 859,343,587 shares of its direct controlling shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd., which accounts for 25.94% of Zhongheng Group's total share capital [1][2] - After the transaction, Guangxi Investment Group Financial Holding Co., Ltd. will become the indirect controlling shareholder of the company, while Zhongheng Group will remain the direct controlling shareholder, and the actual controller will still be the Guangxi State-owned Assets Supervision and Administration Commission [1][2] - The transaction is still in the planning stage and requires approval from state-owned assets authorities and other legal procedures [1][3] Group 2 - Prior to the transaction, Zhongheng Group is the direct controlling shareholder, and Guangxi Investment Group is the indirect controlling shareholder, with the actual controller being the Guangxi State-owned Assets Supervision and Administration Commission [2] - The transaction will not affect the company's normal production and operational activities, as it is a change of state-owned equity under the same control [2]